The following article will concentrate on the NDV-3 anti-Candida and Staphylococcus vaccine. The vaccine is composed of the N-terminal portion of the Candida albicans agglutinin-like sequence 3 protein (Als3p) and aluminum hydroxide as adjuvant. The vaccine conferred protection to mice against experimental vaginal, oral, and intravenous challenge with C. albicans. Due to the sequence and structural homology of the Als3p with Staphylococcus aureus surface proteins, the vaccine also protected against experimental skin and IV infection with S. aureus. The vaccine has reached the stage of human trials: phase 1 clinical studies have shown that the vaccine is safe and immunogenic. The latest brief conference abstract reports of vaccination in women suffering from recurrent vaginal candidiasis, indicating that the recurrence rates were lower in the women receiving the vaccine.
CITATION STYLE
Segal, E. (2017). Testing antifungal vaccines in an animal model of invasive candidiasis and in human mucosal candidiasis. In Methods in Molecular Biology (Vol. 1625, pp. 343–353). Humana Press Inc. https://doi.org/10.1007/978-1-4939-7104-6_23
Mendeley helps you to discover research relevant for your work.